Company* (Symbol)**

University/Non-Profit [Scientist]

Type of Agreement

Product Area

Details (Month)

Abgenix Inc. (ABGX)

U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

Research and development collaboration

Abgenix XenoMouse technology

Abgenix and USAMRIID entered a collaboration in July 1999 to develop antibodies that could potentially protect U.S. troops during biological warfare; USAMRIID received access to Abgenix's XenoMouse technology to make fully human monoclonal anti-bodies against filoviruses; Abgenix expanded the collaboration, granting USAMRIID further access to its XenoMouse technology to make fully human monoclonal antibodies that will be tested for their ability to provide protection against viral infections attributed to poxviruses (10/99)

Affymetrix Inc. (AFFX)

National Cancer Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthrities and Musculo-skeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute of Health Clinical Center

Technology access

Affymetrix GeneChip technology

Agreement allows participating institutes broad access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in research activities; terms and conditions specially designed to allow for broad publication of scientific results and to facilitate collaborations with academic, governmental and commercial scientific colleagues (7/99)

Washington University

Technology access

Affymetrix GeneChip technology

Washington University signed an Academic Access agreement, which gives all Washington University researchers access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression for use in research activities (7/99)

American Biogenetic Sciences Inc. (ABS; MABXA)

Institute of Laboratory Animal Science of the Chinese Academy of Medical Sciences at Beijing Union Hospital

Technology access

ABS Antigen-Free Mouse technology

The ABS mouse colony will be installed at the Institute of Laboratory Animal Science; the core technology will continue to be housed by ABS at its subsidiary, Stellar Bio Systems Inc.; ABS will allow the use of its technology for development and production of monoclonal antibodies; ABS will have worldwide rights to market, sell and license the antibodies developed (7/99)

Antex Biologics Inc.*

Department of the Army, of the U.S. Department of Defense

Development agreement

Antex's nutriment signal transduction technology (NST)

Antex received a small business technology transfer research contract from the Department of the Army for the development of a multivalent, oral vaccine for traveler's diarrhea, using Antex's NST technology (10/99)

Atairgin Technologies Inc.*

M.D. Anderson Cancer Center [Gordon B. Mills, Xianjun Fang]

Research collaboration

Atairgin's platform technology in lysophospholipids

Atairgin and M.D. Anderson entered a research collaboration agreement in 1997, using Atairgin's platform technology to develop an early detection marker for ovarian and other gynecological cancers; Atairgin expanded the collaboration, providing for application of its technology to develop potential therapeutic agents (8/99)

Atlantic Pharmaceuticals (ATLC)

University of Pennsylvania

License agreement

Beta-cyclodextrin tetradecasulfate (B-CDT) to prevent restenosis after cardiac angioplasty

Atlantic and its subsidiary, Channel Therapeutics Inc., terminated their 6/94 license agreement with University of Pennsylvania (10/99)

Aurora Biosciences Corp.(ABSC)

National Cancer Institute (NCI)

Technology access

Aurora's GenomeScreen technology

National Cancer Institute will gain access to Aurora's GenomeScreen technology to identify rare or low abundance transcripts in tumor cells; Aurora will focus on genes that may be missed by other less sensitive gene identification methods (7/99)

Avigen Inc. (AVGN)

Children's Hospital of agreement

License

Factor IX gene therapy using adeno-associated virus

Avigen received worldwide rights to Factor IX gene therapy technology for hemophilia B (7/99)

Boston Life Sciences Inc. (BLSI)

Hebrew University, Hadassah Medical School

License agreement

Anticancer fusion toxins

Boston Life Sciences will develop, under an exclusive worldwide license, a broad-based technology invented by scientists at Hadassah Medical School covering fusion toxins for the treatment of a wide variety of solid tumors, as well as multiple sclerosis and allergies (6/99)

CalBio-Marine Technologies Inc.*

University of California, San Diego (UCSD)

License agreement

Technologies for materials and methods for production of polyketides

CalBioMarine signed a technology license agreement with UCSD for an exclusive license to technologies for materials and methods for the production of polyketides such as the bryostatins developed at UCSD's Scripps Institution of Oceanography (8/99)

Celgene Corp. (CELG)

National Cancer Institute

Collaboration agreement

Thalomid

Celgene and the NCI initiated a Phase II trial using Celgene's Thalomid to treat patients with colorectal cancer (8/99)

Chroma-Vision Medical Systems Inc. (CVSN)

University of Southern California, Kenneth Norris Jr. Comprehensive Cancer Center [Roscoe D. Atkinson]

Development agreement

Automated Cellular Imaging System test for angiogenesis

ChromaVision commenced a clinical partnership to develop an objective tumor angiogenesis test with Atkinson and the university cancer center (9/99)

Ciba Vision (a unit of Novartis AG, Switzerland)

University of Iowa and Université Louis Pasteur (France)

Research collaboration

Biological causes and potential treatments for age-related macular degeneration (AMD)

Ciba, University of Iowa and the eye clinic of Université Louis Pasteur entered a collaborative research agreement to identify the biological causes and potential treatments for AMD and other retinal degenerations; Ciba received the opportunity to license University of Iowa patents, including intellectual property developed prior to or during the collaboration (9/99)

Digital Gene Technologies* (DGT)

Johns Hopkins University School of Medicine and the Jackson Laboratory

Technology access

DGT's TOGA gene expression profiling technology

DGT, Johns Hopkins and Jackson Laboratory will collaborate in an expanded study of neurodegenerative disease using DGT's TOGA (Total Gene Expression Analysis) technology; the collaboration is under the direction of the DGT scientific advisory board, and is designed to advance basic research and encourage publication, with commercial opportunities reserved for DGT (8/99)

EntreMed Inc. (ENMD)

Children's Hospital, Boston [Judah Folkman]

Research agreement

EntreMed's Endostatin and Angiostatin proteins

EntreMed extended its 9/93 research agreement with Folkman's laboratory at Children's Hospital, Boston; EntreMed will continue to fund certain research projects and will have rights to discoveries arising from them; scientists and technicians in Folkman's laboratory will provide research support related to upcoming clinical trials of Endostatin protein and Angiostatin protein (6/99)

Genzyme General (GENZ)

Beth Israel Deaconess Medical Center

Research and development agreement

DHA-based therapy for cystic fibrosis (CF)

Genzyme and researchers at Beth Israel entered a collaboration to develop a cystic fibrosis therapeutic based on the discovery by Beth Israel researchers of a correctable lipid imbalance in a mouse model of CF; Genzyme has been granted an exclusive license to intellectual property related to DHA therapy (10/99)

ICAgen Inc.*

Research Foundation of State University of New York, Stony Brook (SUNY)

License agreement

Ion channel disease targets

ICAgen received an exclusive license from SUNY for novel ion channel genes, discovered by university researchers; further details ND (6/99)

IDEC Pharmaceuticals (IDPH)

National Cancer Institute

Collaboration agreement

IDEC's Zevalin radioimmotherapy treatment

IDEC and the NCI entered a collaboration to broaden clinical studies of Zevalin (ibritumomab tiuxetan) as treatment for conditions outside those currently under investigation by IDEC (8/99)

Immunicon Corp.*

The University of Texas Southwestern Medical Center [Jonathan W. Uhr]

Research and license agreement

Immunicon's rare-cell

The research agreement is for a period detection and analysis platform technologies of three years and provides monetary support and other consideration for research into applications and further development of Immunicon's platform technologies for the diagnosis, staging, treatment and monitoring for recurrence of invasive cancers of epithelial origins; the license agreement grants Immunicon an exclusive worldwide license for commercialization of technology developed under the research agreement; Uhr will act as principal investigator (8/99)

Incyte Pharmaceuticals Inc. (INCY)

Huntsman Cancer Institute

Research collaboration

Incyte's LifeSeq Gold database

Incyte and Huntsman entered a two-year collaboration to study the role of genes in the diagnosis, prevention and treatment of cancer; Huntsman will have access to Incyte's LifeSeq Gold database, as well as the use of Incyte's microarrays and microarray data management software; Incyte will receive access to high-quality tissue and tumor samples, as well as research findings from Huntsman's colon cancer program (9/99)

InSite Vision Inc. (AMEX:ISV)

Uppsala University, Sweden [Claes Wadelius]

Research agreement

InSite's ISV-900 program

InSite and Wadelius signed a glaucoma genetic research agreement that covers investigation on the role of the TIGR gene in primary open angle glaucoma and exfoliative glaucoma patients in a Swedish population; Wadelius will have access to InSite's ISV-900 program, which is designed to explore various use of the TIGR gene and other glaucoma genes for glaucoma diagnosis, prognosis, therapeutic development and disease management (9/99)

LexiconGenetics Inc.*

Rockefeller University

Research agreement

Engineering of custom knockout mice

Lexicon and Rockefeller entered a multi-year functional genomics research agreement for the rapid engineering of custom knockout mice; under the agreement, researchers in the laboratory for which the agreement was made may specify genes for which Lexicon will produce knockout mice using its technologies in homologous recombination, including Cre-lox, positive/negative selection and isogenic DNA; Lexicon will share in commercial applications of gene function discoveries made under the agreement; financial terms ND (8/99)

Lorus Therapeutics Inc. (Canada; TSE:LOR)

National Cancer Institute

Development collaboration

Novel anticancer compounds

Lorus announced an extension of a previous collaboration with the NCI, which has agreed to allocate resources for the further development of three anticancer compounds initially discovered at Harvard Medical School; further details ND (10/99)

MedImmune Inc. (MEDI)

Columbia University

License agreement and research collaboration

Columbia's MAb 15A10 catalytic antibody against cocaine addiction

MedImmune will develop and commercialize Columbia's 15A10 antibody to treat cocaine overdose and addiction; MedImmune will be responsible for worldwide research, clinical development, manufacturing and commercialization of any product resulting from the collaboration; MedImmune will pay a one-time license fee to Columbia, and will make milestone and royalty payments based on clinical development progress and sales of resulting products; Ixsys Inc. will optimize the primary product candidate as part of the four-product antibody alliance it entered into with MedImmune in 2/99 (9/99)

NeoTherapeutics Inc. (NEOT)

University of California, Irvine (UCI) [Olivier Civelli]

Collaborative research and technology

UCI's orphan receptor strategy research technique development agreement

NeoTherapeutics will conduct research with a UCI team headed by Civelli on neurotransmitters and their receptors in the brain; the company awarded Civelli's team $0.9M for three years; NeoTherapeutics will make additional investments totaling $1.1M for further development of the optioned technology; the company may enter strategic partnerships with larger pharmaceutical companies to create drugs from the research and development efforts conducted under the collaboration; the company also will have an option for an exclusive three-year license to work on developing drugs that stem from findings of the UCI team (9/99)

Novavax Inc. (AMEX: NOX)

University of Michigan

Supply agreement

Novavax's proprietary microbicides

Novavax received an extension of its subcontract to supply the University of microbiocides for the development of antimicrobial products against certain biologic warfare agents; the program is funded by the Defense Advanced Research Projects Agency of the U.S. Department of Defense (8/99)

Oxigene Inc. (OXGN)

Arizona State University

License agreement

Arizona State's combretastatin technology

Oxigene acquired an exclusive, worldwide license for the commercial rights to Arizona's combretastatin technology, including the lead compound Combretastatin A-4; further details ND (8/99)

Protein Sciences Corp.*

Texas A&M University

Collaboration agreement

Baculovirus expression vector system (BEVS)

Protein Sciences and Texas A&M signed a definitive agreement to combine their intellectual property and know-how regarding BEVS; Protein Sciences is exclusively authorized to sublicense the combined BEVS technology to third parties in combination with its own proprietary technology (6/99)

Renaissance Cell Technologies (a subsidiary of Incara Pharmaceuticals Corp.; INCR)

University of North Carolina, Chapel Hill (UNC-CH) [Lola M. Reid]

License agreement

Isolation and purification of human liver progenitor cells

Renaissance licensed the exclusive, worldwide rights to patent applications and related technologies for isolating and purifying human liver progenitor cells, developed by Reid at UNC-CH's school of medicine under a previous sponsorship agreement (8/99)

SciClone Pharmaceuticals (SCLN)

University of California, Berkeley (UNC-B)

License agreement [Edward T. Wei]

Class of immunomodulating compounds developed by Wei

SciClone licensed the exclusive rights to a class of compounds developed by Wei; further details ND (8/99)

Sequenom Inc.*

University of Munster (Germany)

Technology access

Sequenom's MassArray SpectroChips technology

The University of Munster received access to Sequenom's MassArray and SpectroChips technology for genetic research in cardiovascular diseases; further details ND (9/99)

SuperGen Inc. (SUPG, SUPGW)

US Oncology

Research agreement

SuperGen's rubitecan and nipent anticancer compounds

SuperGen and US Oncology entered a collaboration in which US Oncology will carry out clinical programs using SuperGen's anticancer compounds; further details ND (9/99)

Third Wave Technologies*

Stanford University

Research collaboration agreement

Third Wave's Invader platform technology for DNA and RNA analysis

Stanford's Human Genome Center will have access to Third Wave's proprietary assay development tools for large-scale development of Invader-based pharmacogenomic assays for use at both the Genome Center and the university; all Stanford researchers will have broad access to the technology for single nucleotide polymorphism, genotyping and gene expression analysis; Stanford will receive preferential pricing for certain reagents for both its pharmacogenomic research and clinical applications; Third Wave will receive certain rights to all discoveries made using its technology; the agreement includes special terms and conitions designed to allow academic researchers freedom to collaborate with others and publish scientific results (10/99)

VistaGen Inc.*

National Jewish Medical and Research Center (NJMRC) [Gordon Keller]

License agreement

NJMRC's embryonic stem cell patents and technology

VistaGen licensed certain exclusive, worldwide rights to embryonic stem cell patents and technology developed by Keller; VistaGen will use the technology to develop embryonic stem cells as a platform for increasing the efficiency of drug discovery and development; further details ND (7/99)

Vysis Inc. (VYSI)

National Human Genome Research Institute (NHGRI) and the Institute of Pathology at the University of Basel (Switzerland)

Research and development agreement

Vysis's GenoSensor and Fluorescence In Situ Hybridization (FISH) systems, NHGRI's tissue microarrays and the university's tumor specimen collection

The three institutions will combine their technologies and products to define amplifications of specific genes in various cancers to determine their potential clinical significance; Vysis has an option to negotiate a license with the National Institutes of Health and/or the University of Basel for inventions that arise from the collaboration (6/99)

Xanthon Inc.*

North Carolina State University (NCSU) [H. Holden Thorp and Neena Grover]

License agreement

NCSU's process of cleaving nucleic acids with oxoruthenium complexes

Xanthon licensed exclusive, worldwide rights from NCSU to patented technology develped by Thorp and Grover; the technology will have commercial applications in future Xanthon products; further details ND (10/99)

ZymeTx Inc. (ZMTX)

Oklahoma Medical Research Foundation (OMRF)

License and development agreement

OMRF's ZX-0851 anti-HIV compound

ZymeTx returned its license to ZX-0851 to OMRF, citing a longer development cycle than originally planned; in return for the license, OMRF will reimburse ZymeTx for its license fee and certain other expenses related to the compound; the return of the license does not affect other, current collaborations between OMRF and ZymeTx (7/99)

Notes:

* Privately held company

** Unless otherwise noted, the stock symbols listed are on the Nasdaq market.

ND = Not disclosed.